|
How to Cite 1. For In-Text Citation (Materials & Methods): 2. For Key Resources Table: |
||
|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. We strive to reply to |
| Formula | C22H23ClFN5O3 |
||||||
| Molecular Weight | 459.90 | CAS No. | 1626387-80-1 | ||||
| Solubility (25°C)* | In vitro | DMSO | 91 mg/mL (197.86 mM) | ||||
| Ethanol | 20 mg/mL (43.48 mM) | ||||||
| Water | Insoluble | ||||||
| In vivo (Add solvents to the product individually and in order) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||
| Description | Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 values of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. This compound is in Phase 1. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
||||||
| In vitro | 在H3255 (L858R)细胞中,Zorifertinib (AZD3759)抑制EGFR磷酸化的IC50为7.2 nM。该化合物对pEGFR通路和EGFR突变衍生细胞PC-9及H3255的增殖均表现出抑制作用,IC50分别为7.7 nM和7 nM,但对H838细胞的增殖无显著活性。[1] | ||||||
| In vivo | Zorifertinib (AZD3759) shows good oral bioavailability in dogs and penetrates extensively into monkey brain. In a brain metastasis PC-9 (Exon19Del) model, this compound (15 mg/kg) causes significant dose-dependent antitumor efficacy. [1] |
| Kinase Assay:[1] |
|
|---|---|
| Cell Assay:[1] |
|
| Animal Study:[1] |
|
|
| A Novel Network Pharmacology Strategy Based on the Universal Effectiveness-Common Mechanism of Medical Herbs Uncovers Therapeutic Targets in Traumatic Brain Injury [ Drug Des Devel Ther, 2024, 18:1175-1188] | PubMed: 38645986 |
| Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling [ Oncogene, 2022, 10.1038/s41388-022-02256-3] | PubMed: 35250028 |
| Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology [ Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7] | PubMed: 33009951 |
| YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer [ Clin Cancer Res, 2019, 25(8):2575-2587] | PubMed: 30670498 |
| IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas [ Cancer Lett, 2019, 458:29-38] | PubMed: 31129148 |
| Brain distribution of a panel of EGFR inhibitors using cassette-dosing in wild-type and Abcb1/Abcg2 deficient mice [Kim M Drug Metab Dispos, 2019, 10.1124/dmd.118.084210] | PubMed: 30705084 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.